Financial reports
10-K
2023 FY
Annual report
20 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
20 Mar 24
8-K
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
29 Jun 23
8-K
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
11 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Apr 23
8-K
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
16 Mar 23
8-K
Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
8-K
Trevi Therapeutics Announces Pricing of $55 Million Public Offering
23 Sep 22
8-K
Corporate Presentation September 2022
19 Sep 22
Registration and prospectus
S-8
Registration of securities for employees
20 Mar 24
S-3/A
Shelf registration (amended)
11 Aug 23
S-3
Shelf registration
29 Jun 23
S-8
Registration of securities for employees
11 May 23
424B5
Prospectus supplement for primary offering
23 Sep 22
424B5
Prospectus supplement for primary offering
22 Sep 22
424B5
Prospectus supplement for primary offering
13 May 22
S-8
Registration of securities for employees
2 May 22
S-3
Shelf registration
2 May 22
D
$55M in equity / options / securities to be acquired, sold $55M, 12 investors
18 Apr 22
Proxies
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
29 May 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
Other
EFFECT
Notice of effectiveness
16 Aug 23
CORRESP
Correspondence with SEC
14 Aug 23
UPLOAD
Letter from SEC
5 Jul 23
EFFECT
Notice of effectiveness
12 May 22
CORRESP
Correspondence with SEC
9 May 22
UPLOAD
Letter from SEC
6 May 22
EFFECT
Notice of effectiveness
17 Nov 21
CORRESP
Correspondence with SEC
12 Nov 21
UPLOAD
Letter from SEC
10 Nov 21
EFFECT
Notice of effectiveness
26 Oct 21
Ownership
4
Christopher Galletta
16 Feb 24
4
Farrell Simon
16 Feb 24
4
David J Clark
16 Feb 24
4
JENNIFER L GOOD
16 Feb 24
4
THOMAS SCIASCIA
16 Feb 24
4
Lisa Delfini
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24